Legal Issues

Wyeth, lawyers for fen-phen users propose new settlement

Published in Cardiovascular Business Week, August 10th, 2004

Former fen-phen users seeking compensation for heart problems under a U.S. class-action settlement would get payments sooner but would receive less under a proposed new agreement between drug maker Wyeth and claimants' attorneys.

The new agreement must be approved by a federal judge after some details are ironed out over the next couple weeks. It would affect about 41,600 former users of the diet drugs Pondimin and Redux who suffered moderate heart valve damage.

Wyeth pulled the drugs, part of the once wildly popular fen-phen combination, from the market in September 1997 amid reports they had caused heart valve damage and, in a small number of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2004-08-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry